NASDAQ: DRRX - DURECT Corporation

Rentabilidade por seis meses: -30.15%
Rendimento de dividendos: 0.00%
Setor: Healthcare

Cronograma de promoção DURECT Corporation

Agenda avançada Gráfico simples
Financial Markets by TradingView

Sobre a empresa DURECT Corporation

DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals.

mais detalhes
It also develops larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine over three days in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Innocoll Pharmaceuticals Limited. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.
Adicionar à lista de comparação
Adicionar à lista de observação
Adicionar ao portfólio
Adicionar aviso de preço

IPO date 2000-09-28
ISIN US2666051048
Industry Pharmaceuticals
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.durect.com
Цена ао 1.27
Alteração de preço por dia: -1.87% (0.9681)
Alteração de preço por semana: 0% (0.95)
Alteração de preço por mês: +4.11% (0.9125)
Alteração de preço em 3 meses: -27.48% (1.31)
Mudança de preço em seis meses: -30.15% (1.36)
Mudança de preço por ano: +61.02% (0.59)
Mudança de preço em 3 anos: -0.2101% (0.952)
Mudança de preço em 5 anos: -51.28% (1.95)
Mudança de preço em 10 anos: 0% (0.95)
Mudança de preço desde o início do ano: -35.37% (1.47)
Todos os parâmetros

Subestimação

Nome Significado Nota
P/S 1.61 8
P/BV 0.9329 9
P/E 0 0
EV/EBITDA -0.167 0
Total: 5.88

Eficiência

Nome Significado Nota
ROA, % -61.13 0
ROE, % -186.86 0
Total: 0

Dividendos

Nome Significado Nota
Div yield, % 0 0
DSI 0 0
Total: 0

Obrigação

Nome Significado Nota
Debt/EBITDA -0.5647 10
Total: 8

Impulso de crescimento

Nome Significado Nota
Rentabilidade Revenue, % -71.12 0
Rentabilidade Ebitda, % 36.38 5
Rentabilidade EPS, % -18.62 0
Total: 1.8
Mais detalhes

Instituições Volume Compartilhar, %
Ingalls & Snyder 2146002 6.91
Vanguard Group Inc 1072489 3.46
Richmond Brothers, Inc. 518294 1.67
Gagnon Securities, LLC 358706 1.16
Blackrock Inc. 338855 1.09
Beirne Wealth Consulting Services, LLC 320051 1.03
Dalton Investments LLC 237334 0.76
Geode Capital Management, LLC 234364 0.76
Tocqueville Asset Management L.P. 231220 0.75
Ironwood Investment Management, LLC 195517 0.63



Supervisor Cargo Pagamento Ano de nascimento
Dr. James E. Brown D.V.M. Co-Founder, CEO, President & Director 633.46k 1957 (68 anos)
Ms. Judy R. Joice Senior Vice President of Operations & Corporate Quality Assurance 451.82k 1957 (68 anos)
Dr. Norman L. Sussman M.D. Chief Medical Officer 471.71k 1953 (72 ano)
Mr. Timothy M. Papp M.B.A. CFO & Secretary 427.62k 1976 (49 anos)
Ms. Jian Li M.B.A. Senior VP of Finance, Corporate Controller & Secretary 297.08k 1970 (55 anos)
Dr. WeiQi Lin M.D., Ph.D. Executive VP of Research & Development and Principal Scientist N/A
Mr. Keith L. Lui M.B.A. Senior Vice President of Business Development, Commercial & Medical Affairs N/A
Dr. Su Il Yum Ph.D. Executive Officer 331.74k 1939 (86 anos)

Endereço: United States, Cupertino. CA -, 10260 Bubb Road - abrir no Google Maps, abrir mapas Yandex
Site: https://www.durect.com